CERo Therapeutics has initiated a Phase 1 clinical trial for its innovative product candidate, CER-1236, targeting acute myeloid leukemia, signifying a key milestone in its development pipeline.

This review explores the role of PET in imaging immune activation, particularly in oncology. 18F-FDG is widely used for assessing treatment response to immunotherapies and can demonstrate unique ...

Pfizer and BioNTech have started a mid-stage trial of a new version of the COVID-19 vaccine based on a version of the spike protein that ... immune response." The phase 2 trial will test a 30 ...

C-reactive protein (CRP) increases rapidly in response to infection and inflammation. CRP provides a link between the innate and adaptive immune systems by activation of complement and interaction ...

A new study conducted in Italy reveals a reduction in long-COVID burden 7 months following the acute phase. The study, published in BMC Infectious Diseases, also shows that one-third of patients ...

Neurofilament light chain (NfL) is a protein biomarker in body fluids that is unique to ... Axonal damage and loss are the pathological substrate of NfL in acute and chronic neurological disorders, ...

Within a few weeks after first visit, he developed acute symptomatic worsening kidney injury with ... Initial urinalysis showed no protein, red cells or white cells. Twenty-four hours urine protein ...